Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
about
Endogenous retinoids in the pathogenesis of alopecia areataHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsInterleukin-7 and interleukin-15 for cancerHDAC inhibitors and immunotherapy; a double edged sword?NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaValproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.Oncogenic stress sensed by the immune system: role of natural killer cell receptorsSelective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human Natural Killer cellsSpecific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemiaNovel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association studyMatrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia.Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity.Combination immune therapies to enhance anti-tumor responses by NK cells.Immunotherapy prospects for acute myeloid leukaemia.Combining immunotherapy and targeted therapies in cancer treatment.Natural killer cell immune escape in acute myeloid leukemia.Targeting NKG2D in tumor surveillance.Combination strategies to enhance antitumor ADCC.Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activityγδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Exploiting natural killer group 2D receptors for CAR T-cell therapy.NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AMLThe safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.Matrine regulates immune functions to inhibit the proliferation of leukemic cells.How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases.MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells.Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.
P2860
Q24632863-56994420-047F-4F10-9EAB-EC4877BDC122Q24633763-A0ECD445-261B-4179-BA5E-54DFE3181776Q26751011-ECDC93BA-7FC5-4281-8FA8-BD62501CE259Q26830709-7E0BC200-F110-414C-814C-FCC7AEE0CB41Q26853102-5104AC22-835D-4086-A140-49E23A93F514Q28080823-539B6887-9822-459A-B83A-6DFDDB9C6599Q33825014-2B5649FF-8D0A-4534-BB47-007592B944BFQ34473267-DA9F9908-B0A2-4444-8ADE-DEAF34A5F648Q34717893-2B3D0828-78ED-4197-888C-F3B5D8000F1DQ35664342-6DC4CB67-88A9-4975-BE6C-D2FC161AB336Q36211604-DD036FC8-745B-43E4-8485-C20FD691007CQ36309488-A50B5C5B-6033-409E-98F9-AD54604A219AQ36520715-C262F389-1288-49BA-BF2E-31ED5F0B283AQ36829028-B5E4C36C-1582-49C9-8336-7659A28C735EQ37408550-3C790E9A-39FB-4010-B965-DEFFD59D5C34Q37763280-1F184FD3-B73F-4D38-9B84-320A76B5A0B3Q37995939-6A579779-80CD-47BE-B242-EEFD7619E1AAQ37996816-76819F41-2AFC-4D34-9620-B64FF73351B6Q38005176-8E2C8922-5641-41E5-A7FD-61421F6A9EDCQ38014085-F276537E-D23B-4E03-B1CA-E717B5E4DF10Q38035301-1F6AF148-8AD4-423F-9B07-1E5ECFF153CFQ38107250-C33532D7-C1AB-4FD8-A28C-3DD4005CA6E6Q38203261-B06F735B-36B6-45A0-B0DA-7AE7B42FFF0AQ38271585-D93BE0A6-1DFC-4738-B595-DF4C387B7131Q38671184-F59D94F1-DB21-4C89-8419-0CEA3E1BF4F8Q38847073-89F1B303-5D30-4C68-BD59-AA33635D57CAQ38910282-68A3F377-D0BF-4322-8AC9-280B175C80FAQ38940720-A50C6B5E-396D-4053-B620-E5159E736EF7Q39158802-20592B39-23ED-43DC-AB4E-3177B08595B8Q39323511-97C03AC3-40B7-4EF0-8781-47EC9D79909FQ39436145-705F86C5-AC21-4AB3-A2CA-9A299F0AD80CQ40596798-900D8F2C-65F0-47FC-85D3-72D8D88E84B8Q41639162-ACB6D3AB-9561-4028-A863-23682A2559DBQ42740131-7A66513B-FF12-4ADB-B807-3E1E684628CFQ43497561-D26F9A2B-9276-488D-90FB-39B34CE1CB53Q43555934-DBC8D527-1145-41F4-B4F3-83B68D38B01BQ44385638-6E7D9329-5926-4E16-A0D7-BCCB1A8BCD43Q45009828-B3ED370A-8123-42FF-82FE-3F7F914ED992Q45759422-C87D7FC1-1AE9-492A-BB96-00ED67023B97Q51645804-E98318A5-3E44-4F12-A5FD-FD78FE1983EB
P2860
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effective in vivo induction of ...... noic acid or sodium valproate.
@en
Effective in vivo induction of ...... noic acid or sodium valproate.
@nl
type
label
Effective in vivo induction of ...... noic acid or sodium valproate.
@en
Effective in vivo induction of ...... noic acid or sodium valproate.
@nl
prefLabel
Effective in vivo induction of ...... noic acid or sodium valproate.
@en
Effective in vivo induction of ...... noic acid or sodium valproate.
@nl
P2093
P2860
P356
P1433
P1476
Effective in vivo induction of ...... noic acid or sodium valproate.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2008.354
P577
2009-01-08T00:00:00Z
P5875
P6179
1037944702